Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
editorial
. 1984;3(4):282–284. doi: 10.1007/BF01977473

Interferons and viral infections

P G Higgins 1
PMCID: PMC7087989  PMID: 6208021

The content is available as a PDF (270.1 KB).

References

  • 1.Baron S., Dianzani F. General consideration of the interferon system. Texas Reports on Biology and Medicine. 1977;35:1–10. [PubMed] [Google Scholar]
  • 2.Isaacs D., Clarke J. R., Tyrrell D. A. J., Webster A. D. B., Valman H. B. Deficient production of leucocyte interferon (interferon-α) in vitro and in vivo in children with recurrent respiratory tract infection. Lancet. 1981;ii:950–952. doi: 10.1016/s0140-6736(81)91153-3. [DOI] [PubMed] [Google Scholar]
  • 3.Levin S., Hahn T. Interferon system in acute virus hepatitis. Lancet. 1982;i:592–594. doi: 10.1016/s0140-6736(82)91751-2. [DOI] [PubMed] [Google Scholar]
  • 4.Scott G. M., Cartwright T., LeDu G., Dicker D. Effect of human fibroblast interferon on vaccination in volunteers. Journal of Biological Standardization. 1978;6:73–76. doi: 10.1016/s0092-1157(78)80036-5. [DOI] [PubMed] [Google Scholar]
  • 5.Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. J. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973;i:563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  • 6.Scott G. M., Phillpotts R. J., Wallace J., Secher D. S., Cantell K., Tyrrell D. A. J. Purified interferon as protection against rhinovirus infection. British Medical Journal. 1982;i:1822–1825. doi: 10.1136/bmj.284.6332.1822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Samo T. C., Greenberg S. B., Couch R. B., Quarles J., Johnson P. E., Hook S., Harmon M. W. Efficacy and tolerance of intranasally applied recombinant leucocyte A interferon in normal volunteers. Journal of Infectious Diseases. 1983;148:535–542. doi: 10.1093/infdis/148.3.535. [DOI] [PubMed] [Google Scholar]
  • 8.Hayden F. G., Gwaltney J. M. Intranasal interferonα2 for prevention of rhinovirus infection and illness. Journal of Infectious Diseases. 1983;148:543–550. doi: 10.1093/infdis/148.3.543. [DOI] [PubMed] [Google Scholar]
  • 9.Higgins P. G., Phillpotts R. J., Scott G. M., Wallace J., Bernhardt L. L., Tyrrell D. A. J. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrobial Agents and Chemotherapy. 1983;24:713–715. doi: 10.1128/aac.24.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Pazin G. J., Armstrong J. A., Lam M. T., Tarr G. C., Jannetta P. J., Ho M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. New England Journal of Medicine. 1979;301:225–230. doi: 10.1056/NEJM197908023010501. [DOI] [PubMed] [Google Scholar]
  • 11.Cheeseman S. H., Rubin R. H., Stewart J. A., Tolkoff-Rubin N. E., Cosimi A. B., Cantell K., Gilbert J., Winkle S., Herrin J. T., Black P. H., Russell P. S., Hirsch M. S. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. New England Journal of Medicine. 1979;300:1345–1349. doi: 10.1056/NEJM197906143002401. [DOI] [PubMed] [Google Scholar]
  • 12.Hirsch M. S., Schooley R. T., Cosimi A. B., Russell P. S., Delmonico F. L., Tolkoff-Rubin N. E., Herrin J. T., Cantell K., Farrell M. L., Rota T. R., Rubin R. H. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. New England Journal of Medicine. 1983;308:1489–1493. doi: 10.1056/NEJM198306233082501. [DOI] [PubMed] [Google Scholar]
  • 13.Jones B. R., Coster D. J., Faloon M. G., Cantell K. Topical therapy of ulcerative herpectic keratitis with human interferon. Lancet. 1976;ii:128. doi: 10.1016/s0140-6736(76)92850-6. [DOI] [PubMed] [Google Scholar]
  • 14.Sundmacher R., Neumann-Haefelin D., Cantell K. Successful treatment of dendritic keratitis with human leucocyte interferon — a controlled clinical study. Graefes Archiv für Klinische und Experimentelle Opthalmologie. 1976;201:39–45. doi: 10.1007/BF00410146. [DOI] [PubMed] [Google Scholar]
  • 15.Sundmacher R., Cantell K., Neumann-Haefelin D. Combination therapy of dendritic keratitis with trifluorothymidine and interferon. Lancet. 1978;ii:687. doi: 10.1016/s0140-6736(78)92809-x. [DOI] [PubMed] [Google Scholar]
  • 16.Merigan T. C., Rand K. H., Pollard R. B., Abdallah P. S., Jordan G. W., Fried R. P. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. New England Journal of Medicine. 1978;298:981–987. doi: 10.1056/NEJM197805042981801. [DOI] [PubMed] [Google Scholar]
  • 17.Arvin A. M., Kushner J. H., Feldman S., Baehner R. L., Hammond D., Merigan T. C. Human leukocyte interferon for the treatment of varicella in children with cancer. New England Journal of Medicine. 1982;306:761–765. doi: 10.1056/NEJM198204013061301. [DOI] [PubMed] [Google Scholar]
  • 18.Greenberg H. B., Pollard R. B., Lutwick L. I., Gregory P. B., Robinson W. S., Merigan T. C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. New England Journal of Medicine. 1976;295:517–522. doi: 10.1056/NEJM197609022951001. [DOI] [PubMed] [Google Scholar]
  • 19.Scullard G. H., Pollard R. B., Smith J. L., Sacks S. L., Gregory P. B., Robinson W. S., Merigan T. C. Anti-viral treatment of chronic hepatitis B virus infection. 1. Changes in viral markers with interferon combined with adenine arabinoside. Journal of Infectious Diseases. 1981;143:772–783. doi: 10.1093/infdis/143.6.772. [DOI] [PubMed] [Google Scholar]
  • 20.Arvin A. M., Schmidt N. J., Cantell K., Merigan T. C. Alpha interferon administration to infants with congential rubella. Antimicrobial Agents and Chemotherapy. 1982;21:259–261. doi: 10.1128/aac.21.2.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Emödi G., O'Reilly R., Müller A., Everson L. K., Binswanger U., Just M. Effect of human exogenous leukocyte interferon in cytomegalovirus infections. Journal of Infectious Diseases. 1976;133:A199–204. doi: 10.1093/infdis/133.supplement_2.a199. [DOI] [PubMed] [Google Scholar]
  • 22.Arvin A. M., Yeager A. S., Merigan T. C. Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. Journal of Infectious Diseases. 1976;133:A205–210. doi: 10.1093/infdis/133.supplement_2.a205. [DOI] [PubMed] [Google Scholar]
  • 23.Ikić D., Bosnić N., Smerdel S., Jušić D., Šooš E., Delimar N. In: Ikić D., editor. Double blind clinical study with human leukocyte interferon in the therapy of condylomata acuminata; Zagreb: Yugoslav Academy of Sciences and Arts; 1975. pp. 229–233. [Google Scholar]
  • 24.Scott G. M., Csonka G. W. Effect of injections of small doses of human fibroblast interferon into genital warts: a pilot study. British Journal of Venereal Disease. 1979;55:442–445. doi: 10.1136/sti.55.6.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Haglund S., Lundquist P. G., Cantell K., Strander H. Interferon therapy in juvenile laryngeal papillomatosis. Archives of Otolaryngology. 1981;107:327–332. doi: 10.1001/archotol.1981.00790420001001. [DOI] [PubMed] [Google Scholar]
  • 26.Phillpotts R. J., Scott G. M., Higgins P. G., Wallace J., Tyrrell D. A. J., Gauci C. L. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-α2. Antiviral Research. 1983;3:121–136. doi: 10.1016/0166-3542(83)90034-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Merigan T. C., Gallagher J. G., Pollard R. B., Arvin A. M. Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer. Antimicrobial Agents and Chemotherapy. 1981;19:193–195. doi: 10.1128/aac.19.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from European Journal of Clinical Microbiology are provided here courtesy of Nature Publishing Group

RESOURCES